I Suarez-Lozano - Academia.edu (original) (raw)

Related Authors

A. Burgos

Universidad Autónoma del Estado de Morelos

Alex Ferreira

Carlos Cortes

Uploads

Papers by I Suarez-Lozano

Research paper thumbnail of Risk factors for end-stage liver disease among HIV and hepatitis C virus co-infected patients in the Spanish VACH Cohort

Journal of the International AIDS Society, 2008

Research paper thumbnail of Response to HAART according to sex and origin (immigrant vs autochthonous) in a cohort of patients who initiate antiretroviral treatment

Journal of the International AIDS Society, 2010

Research paper thumbnail of First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort

Journal of Antimicrobial Chemotherapy, 2008

Background: Efavirenz and lopinavir/ritonavir are both recommended antiretroviral agents for comb... more Background: Efavirenz and lopinavir/ritonavir are both recommended antiretroviral agents for combination first-line therapy, although information on direct comparisons between them is scarce. A retrospective longitudinal study from the VACH cohort comparing both regimens was performed.

Research paper thumbnail of Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort

Journal of Antimicrobial Chemotherapy, 2008

Background: Preliminary data suggest that a once-daily combination of lamivudine, didanosine and ... more Background: Preliminary data suggest that a once-daily combination of lamivudine, didanosine and efavirenz is an effective alternative regimen for antiretroviral-naive HIV-1-infected patients. However, data from randomized trials comparing this combination versus standard first-line regimens are not available yet. In an observational study, we analyse the efficacy and tolerability of didanosine plus lamivudine and efavirenz versus zidovudine plus lamivudine and efavirenz in a cohort of therapy naive patients.

Research paper thumbnail of Dyslipidemia and Cardiovascular Disease Risk Factor Management In HIV-1-Infected Subjects Treated With HAART In the Spanish VACH Cohort

The Open AIDS …, 2008

Background: There is increasing evidence that metabolic adverse effects associated with antiretro... more Background: There is increasing evidence that metabolic adverse effects associated with antiretroviral therapy may translate into an increased cardiovascular risk in HIV-1-infected patients.

Research paper thumbnail of The relationship between antiretroviral prescription patterns and treatment guidelines in treatment-naïve HIV-1-infected patients

Research paper thumbnail of Risk factors for end-stage liver disease among HIV and hepatitis C virus co-infected patients in the Spanish VACH Cohort

Journal of the International AIDS Society, 2008

Research paper thumbnail of Response to HAART according to sex and origin (immigrant vs autochthonous) in a cohort of patients who initiate antiretroviral treatment

Journal of the International AIDS Society, 2010

Research paper thumbnail of First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort

Journal of Antimicrobial Chemotherapy, 2008

Background: Efavirenz and lopinavir/ritonavir are both recommended antiretroviral agents for comb... more Background: Efavirenz and lopinavir/ritonavir are both recommended antiretroviral agents for combination first-line therapy, although information on direct comparisons between them is scarce. A retrospective longitudinal study from the VACH cohort comparing both regimens was performed.

Research paper thumbnail of Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort

Journal of Antimicrobial Chemotherapy, 2008

Background: Preliminary data suggest that a once-daily combination of lamivudine, didanosine and ... more Background: Preliminary data suggest that a once-daily combination of lamivudine, didanosine and efavirenz is an effective alternative regimen for antiretroviral-naive HIV-1-infected patients. However, data from randomized trials comparing this combination versus standard first-line regimens are not available yet. In an observational study, we analyse the efficacy and tolerability of didanosine plus lamivudine and efavirenz versus zidovudine plus lamivudine and efavirenz in a cohort of therapy naive patients.

Research paper thumbnail of Dyslipidemia and Cardiovascular Disease Risk Factor Management In HIV-1-Infected Subjects Treated With HAART In the Spanish VACH Cohort

The Open AIDS …, 2008

Background: There is increasing evidence that metabolic adverse effects associated with antiretro... more Background: There is increasing evidence that metabolic adverse effects associated with antiretroviral therapy may translate into an increased cardiovascular risk in HIV-1-infected patients.

Research paper thumbnail of The relationship between antiretroviral prescription patterns and treatment guidelines in treatment-naïve HIV-1-infected patients

Log In